Ankit Mahadevia

Ankit A. Mahadevia was the founder of Spero Therapeutics, Inc., founded in 2013, where the title held was Director from 2025 to 2026.
Dr. Mahadevia was the founder of Synlogic, Inc., founded in 2013, where the title held was Chief Executive Officer & Director from 2013 to 2016.
Dr. Mahadevia was also the founder of Annovation BioPharma, Inc.,Arteaus Therapeutics LLC,Rodin Therapeutics, Inc...
Dr. Mahadevia previously served as Independent Director at Judo Bio, Inc. since 2023.
Dr. Mahadevia currently serves as Director-Technology Transfer Alliance at The Johns Hopkins University since 2014.
Former positions include Director at Translate Bio, Inc.; Director at Lumavita AG from 2008 to 2014; Principal at Genentech, Inc.; Principal at Vanda Pharmaceuticals, Inc.; Consultant at The Monitor Group, Inc.; Chief Business Officer at Arcion Therapeutics LLC; Principal at Nimbus Therapeutics LLC; Associate at McKinsey & Co., Inc.; Principal at Sirion Therapeutics, Inc.; Principal at JenaValve Technology, Inc.; President at Synlogic Operating Co., Inc.; Advisor at National Center for Advancing Translational Sciences from 2011 to 2015; Advisor at Atlas Venture Life Science Advisors LLC from 2022 to 2023.
Education includes undergraduate degree from Northwestern University, MBA from The Wharton School of the University of Pennsylvania, and doctorate from The Johns Hopkins University School of Medicine.